RxDoctor Payments Data

Jeffrey Akerson, MD

Family Medicine · Bellevue, NENPI 1497834394

Payments from drug & device makers

$3,367in general payments, 2019–2025

Across 144 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Boehringer Ingelheim$337
  • Pfizer$315
  • AstraZeneca$243
  • Amgen$233
  • Gilead$205
  • plus $945 from 16 others

What the payments were for

  • Food & beverage$3,367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,367 in reported general payments places this provider in the 80th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$127,909
Medicare patients
521
Services billed
1,904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$119,533
JardianceEmpagliflozin37$53,763
OzempicSemaglutide40$33,978
TrulicityDulaglutide21$21,781
EntrestoSacubitril/Valsartan19$17,435
XareltoRivaroxaban12$15,179
JanuviaSitagliptin Phosphate16$15,042
SymbicortBudesonide/Formoterol Fumarate28$11,993
Tresiba Flextouch U-100Insulin Degludec16$8,772
Breo ElliptaFluticasone/Vilanterol14$5,462
Praluent PenAlirocumab12$5,375
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,093
CeftriaxoneCeftriaxone Sodium11$4,979
Albuterol Sulfate HfaAlbuterol Sulfate89$2,529
Levothyroxine Sodium190$2,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$315$119,533124 claims
Boehringer IngelheimJardiance$337$53,76337 claims
Novo NordiskOzempic$36$33,97840 claims
NovartisEntresto$1,089$17,43519 claims
Johnson & JohnsonXarelto$18$15,17912 claims
MerckJanuvia$109$15,04216 claims
AstraZenecaSymbicort$243$11,99328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Bellevue

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →